Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732420 · ClinicalTrials.gov registry record · Phase 1
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
A Phase 1 study of Solid Tumours, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 3
- Study locations
NCT00732420: Completed Phase 1 study of Solid Tumours, sponsored by GlaxoSmithKline.
NCT00732420 is a Phase 1 study of Solid Tumours that has completed, run by GlaxoSmithKline. The registered enrollment target is 68 participants, below the 139-participant average among 9 other Solid Tumours trials with a reported enrollment target (51% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00732420, a Phase 1 study of Solid Tumours, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 3
- Study locations
Study Summary
To determined what dose of topotecan can be safely given with daily pazopanib.
Conditions Studied
Interventions
- DRUG topotecan
- DRUG pazopanib
Study Locations (3)
Other
- GSK Investigational Site - Amsterdam
- GSK Investigational Site - Utrecht
Pennsylvania
- GSK Investigational Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2008-09-24 |
| Est. Completion | 2013-06-12 |
| Phase | Phase 1 |
What the finished NCT00732420 record still lists
NCT00732420 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, below the 139-participant average among 9 other Solid Tumours trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Solid Tumours appearing as the primary indexed condition, and to 2 interventions - of which topotecan is the first listed.
NCT00732420 reports a single indexed study location in Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00732420 about?
NCT00732420 is a clinical study titled "Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors". To determined what dose of topotecan can be safely given with daily pazopanib.
What is the current status of trial NCT00732420?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2008-09-24. Estimated completion is 2013-06-12.
What conditions does trial NCT00732420 study?
This clinical trial studies the following conditions: Solid Tumours.
What interventions are being tested in trial NCT00732420?
The interventions under investigation include: topotecan (DRUG), pazopanib (DRUG).
Who is sponsoring clinical trial NCT00732420?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00732420 being conducted?
This trial has 3 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00732420's enrollment target sits among peer trials
68 6th of 9 higher than 4 of 9 other Solid Tumours trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumours trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RECRUITING · Phase 1
-
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
COMPLETED · Phase 1
-
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
COMPLETED · Phase 1
-
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI